Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Long-term Immune, Neurobiological, and Gut-vaginal-urinary axis Exhaustion post-UTI: Research and Rehabilitation

Obiettivo

Urinary tract infections (UTIs) affected an estimated 404.6 million people globally in 2019, contributing to nearly 236,786 deaths and 5.2 million Disability-Adjusted Life Years. For a substantial subset of patients (approximately 25–70% of women), a first UTI is not an isolated event but the beginning of a self-reinforcing cycle of recurrence, repeated antibiotic exposure, microbiome disruption, and epithelial vulnerability. The LINGER project (Long-term Immune, Neurobiological, and Gut–vaginal–urinary axis Exhaustion post-UTI: Research and Rehabilitation) aims to provide the first comprehensive molecular characterisation of this post-infection recurrence state and to deliver diagnostic tools, validated interventions, and structured rehabilitation strategies to transform its management.

LINGER is structured around three objectives. (1) Map & Stratify: establish a pan-European cohort of pre-menopausal women (18–50 years) across Germany, the Netherlands, and Italy, and apply integrated multi-omics (targeted genome sequencing, metagenomics, metatranscriptomics, proteomics/peptidomics, epigenomics, and metabolic modelling) and AI-driven analysis to develop the Virtual Urinary-Tract Twin, a predictive model of post-infection recurrence risk. (2) Dissect & Validate: use in vitro (3D urothelial models) and in vivo (mouse rUTI models) systems to identify and validate causal mechanisms. (3) Intervene & Empower: translate findings into a precision Bacterial-Like Particle (BLiP) mucosal immunotherapy, pilot a digital-first patient self-management and education platform (Post-UTI Recovery Programme), and conduct a comprehensive burden-of-illness assessment to support healthcare integration.

By delivering a predictive diagnostic tool, a Phase 1-ready immunotherapy candidate, and an evidence-based digital care platform, LINGER will shift rUTI management from reactive antibiotic use to proactive, precision prevention, advancing innovations from TRL 2–3 to TRL 4–5.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2026-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Contributo netto dell'UE
€ 1 084 372,50
Indirizzo
LUDWIGSTRASSE 23
35390 GIESSEN
Germania
Regione
Berlin Berlin Berlin
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partecipanti (13)